Dynamics of morbidity, histological structure, contingents and survival of patients with malignant tumors of the lip (population-based study)

Abstract

Introduction. Malignant tumors of the lip (C00) are rare tumor, and mainly affect men. Annually in Russia there are nearly 3000 new cases of malignant tumors of the lip (2011 - 2013). In 2000 there were registered more than 5000 cases. The positive dynamics of morbidity and mortality from this location was marked. Separately to analyze the dynamics of mortality from malignant tumors of the lip cannot be performed because the State Statistics Committee provides only aggregated data for all three-digit rubrics - malignant tumors of the lip, oral cavity and pharynx (S00-14). From 2000 to 2013 the number of deaths in this group according to both sexes increased from 8980 to 9445 or by 5.2%. According to the International Agency for Research on Cancer (IARC) the incidence rate of the population in various countries is also small (except Australia). Aims and objectives. To conduct a study of prevalence of malignant tumors of the lip at the population-based level and to estimate survival rates. Methods. For the first time in Russia there were estimated the rates of morbidity and survival of patients with malignant tumors of the lip by international standards. Paying attention to limited parameters that characterize malignant tumors of the lip in the state report, the main focus was aimed at database of Russia’s first Population-based Cancer Registry of St. Petersburg working according to international standards. For the first time in Russia there is presented dynamics of a 5-year observed and relative survival of patients with malignant tumors of the lip. Results. For the first time in Russia there is provided the structure of morbidity of malignant tumors of the lip according to the 4th digits of ICD-10. There is underlined its stable distribution with decreasing of С00.9 rubrics (undefined parts of lips), showed a significant reduction in morbidity and average relative 5-year survival closed to the European rates.